29 / 164
159
insulin resistance is related to increased circulating fatty acids
and fat oxidation but not muscle lipid content. Metabolism
2003; 52: 699-704.
41. Boden WE, Probstfield JL, Anderson T, et al. AIM-HIGH
Investigators. Niacin in patients with low HDL cholesterol levels
receiving intensive statin therapy. N Engl J Med 2011; 365:
2255-2267
42. Haynes R, Jiang L, Hopewell JC, et al. HPS2-THRIVE Collaborative
Group. HPS2-THRIVE randomized placebo-controlled trial
in 25 673 high-risk patients of ER niacin/laropiprant: trial
design, pre-specified muscle and liver outcomes, and reasons
for stopping study treatment. Eur Heart J 2013; 34: 1279-
1291.
43. Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and
cardiovascular outcomes in patients with dysglycemia. N Engl J
Med 2012; 367: 309-318.
44. Roncaglioni MC, Tombesi M, Avanzini F, e al. n-3 fatty acids in
patients with multiple cardiovascular risk factors. N Engl J Med
2013; 368: 1800-1808.
[DISLIPIDEMIA DIABÉTICA - Dra. Ada Cuevas M. y col.]